PHASE 6 — FORMULATION DESIGN & PHARMACOKINETIC MODELING | AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation

Phase Code: SCF-CF-AEROVIA201-EBP-P6-0001

Objective: Define the inhaled formulation strategy and preliminary PK/PD model for localized pulmonary elastase modulation in cystic fibrosis.

6.1 Formulation Objective

Develop AEROVIA-201 as a lung-localized therapy with:

Requirement	Target Profile
Route	Inhaled
Primary dosage form	Dry powder inhaler
Backup dosage form	Nebulized liposomal suspension
Lung exposure	High
Plasma exposure	Low
Pulmonary residence	8–24 hours
CF mucus penetration	High
Chronic-use suitability	Required

6.2 Primary Formulation: Dry Powder Inhalation

Parameter	Target
Aerodynamic particle size	1–5 µm
Delivered dose uniformity	High
Moisture stability	High
Inspiratory-flow compatibility	Moderate to high
Excipient burden	Low
Device complexity	Low to moderate

Preferred development rationale: DPI offers stability, portability, and potential once-daily chronic administration.

6.3 Backup Formulation: Nebulized Liposomal Suspension

Parameter	Target
Vesicle size	Pulmonary-compatible nanoscale range
Mucus penetration	Enhanced
Local retention	Extended
Systemic leakage	Minimized
Use case	Advanced disease or low inspiratory capacity

Backup rationale: Nebulized delivery may benefit patients with advanced pulmonary limitation who cannot generate adequate inspiratory flow.

6.4 Muco-Penetration Strategy

Barrier	Engineering Response
Dehydrated CF mucus	Hydrophilic surface engineering
Electrostatic trapping	Near-neutral particle surface charge
Sputum protease burden	Protease-stable API/excipient system
Biofilm-associated obstruction	Compatibility with anti-biofilm adjuncts
Variable airway pH	pH-stable formulation window

6.5 Preliminary PK Model

PK Parameter	Target
Lung Tmax	<2 hours
Lung half-life	8–24 hours
Plasma half-life	Short to moderate
Lung/plasma ratio	High
Accumulation	Low to controlled
Metabolism	Minimal pulmonary toxicity metabolites

6.6 Preliminary PD Model

PD Marker	Expected Direction
Sputum neutrophil elastase	Decrease
MMP-9	Decrease
IL-8	Decrease or stabilization
ECM degradation markers	Decrease
FEV1 decline rate	Slower progression
Exacerbation frequency	Potential reduction

6.7 PK/PD Linkage Model

Inhaled AEROVIA-201 dose
      ↓
Pulmonary deposition
      ↓
Mucus penetration
      ↓
Local elastase exposure interface
      ↓
Reduced elastase activity
      ↓
Reduced ECM degradation + MMP activation
      ↓
Lower airway structural injury signal
      ↓
Clinical preservation signal

6.8 Formulation Screening Panel

Study	Purpose
Cascade impaction	Aerodynamic particle performance
Sputum-mimetic diffusion assay	CF mucus penetration
Nebulization stress test	Backup formulation compatibility
Chemical stability assay	API degradation profile
Lung epithelial cytotoxicity	Local tolerability
Macrophage uptake assay	Pulmonary immune compatibility
PK pilot study	Lung/plasma exposure ratio

6.9 SCF Formulation Alignment

SCF Principle	Phase 6 Alignment
Targeted Drug Action	Direct lung delivery to protease injury site
Pharmacokinetic Optimization	High pulmonary exposure, low systemic exposure
Metabolic Efficiency	Reduced systemic metabolic burden
Resistance Prevention	Partial modulation, host-defense monitoring
Safety Profile	Localized dosing with pulmonary tolerability gates

6.10 Phase 6 Decision

Preferred formulation:

Dry powder inhaled AEROVIA-201.

Backup formulation:

Nebulized liposomal AEROVIA-201 for advanced CF lung disease.

Decision:

PROCEED TO PHASE 7 — RESISTANCE PREVENTION & SAFETY MODELING

MASTER REGISTRY INDEX

SCF-CF-AEROVIA201-EBP-P6-0001 — Formulation Design & Pharmacokinetic Modeling

SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator

SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework

SCF-CMC-0001 — Chemistry, Manufacturing & Controls Framework

SCF-SEF-MD-0001 — Synergistic Evaluation Framework

SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow